Trial Profile
A study to evaluate the effect of Tocilizumab in the treatment of Juvenile Idiopathic Arthritis (JIA)-associated uveitis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Dec 2017
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Juvenile rheumatoid arthritis; Uveitis
- Focus Therapeutic Use
- 08 Nov 2017 Results presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
- 01 Oct 2016 Results published in the Arthritis and Rheumatology
- 08 Feb 2016 New trial record